-
Most Recent
coronavirus
Southwest Is a Much Better Pick Now Than American Airlines Stock
Investors looking to play the rebound in airline stocks should pass up AAL stock because the firm's shaky finances will hurt its recovery.
Slim Vaccine Chances Make iBio Stock Too Speculative Here
Every investor is betting on a vaccine. Unfortunately, the case for IBIO stock is simply too speculative, as its trials remain under wraps.
Beyond Meat Stock Is A New Fad That Will Fade Fast
With the meat supply chain shuttered, BYND stock has skyrocketed. However, the fake meat industry can’t rely on such catalysts forever.
Don’t Rush to Buy Delta Stock, There’s Plenty of Time to Bottom Fish
DAL stock isn't the best pick in the airline sector, and with conditions as bad as they are right now, investors should be choosy about their selection.
Regeneron Stock Is a Solid Long-Term Buy
Investors are excited about Regeneron stock for its Covid-19 treatment. They're missing the point. Regeneron is a great long-term buy.
Inovio Stock Poised for Growth as Preliminary Research Shows Promise
Vaccine trials are in progress, and although it isn't the only player on the field, Inovio stock has a clear head-start on the competition.
Buy iBio Stock as an Effective Vaccine Could Be Imminent
Seemingly everyone in the investing world is betting on a coronavirus vaccine. Here's why IBIO stock is a great way to play that trend.
Co-Diagnostics’ Test Kits Still Make CODX Stock a Great Buy
Co-Diagnostics benefits from the quantity and quality of its test kits. This means CODX stock should long be one of investors' favorites.
Don’t Rush to Buy Delta Stock Right Now
DAL stock struggled to recover from the Great Recession. Here's why its recovery from the coronavirus pandemic will be even uglier.
Here’s How PayPal Stock Is Ringing Up Massive Gains
PayPal stock has already jumped in 2020. However, it could have much farther to run as stores rush to promote contactless payments.
Remdesivir Can’t Cure Covid, But Good Luck Telling Gilead Stock
Gilead is moving into commercial production of Remdesivir, a COVID-19 treatment with an aggressive pricing model, but other biotech solutions could come out ahead; it's early days still.
Undervalued Anheuser Busch Stock Has a Bad Case of Market Irrationality
So far, Anheuser Busch stock hasn’t been able to capitalize on increased alcohol demand from the coronavirus. However, it’s only a matter of time before the market realizes the logical opportunity in BUD.
Dow Jones Today: Another Round of Unemployment Data Dragged Stocks
Over the course of the novel coronavirus pandemic, investors are getting accustomed to Thursday misery in the form of the weekly jobless claims data, but markets don't always respond in kind. There have been days when stocks were drubbed on the claims data and others when equities rallied on bleak numbers. Today was somewhere in the middle as the losses weren't terrible.
